Can Eli Lilly and Company’s Omvoh reset expectations for long-term Crohn’s disease control?
Three-year Omvoh data shows durable steroid-free remission in Crohn’s disease. Read how this reshapes Eli Lilly and Company’s long-term strategy.
Can DraftKings Inc and FanDuel unlock Arkansas sports betting growth despite a 51 percent revenue share burden?
Discover how FanDuel and DraftKings are seeking Arkansas sports betting entry under a strict revenue-sharing rule and what it means for the market.
Google unveils Gemini 3.1 Pro and signals a turning point in artificial intelligence reasoning
Find out why Google’s Gemini 3.1 Pro signals a major shift in artificial intelligence reasoning and what it means for enterprises, developers, and investors.
AbbVie Inc. (NYSE: ABBV) wins FDA approval for Venclexta and acalabrutinib in first-line chronic lymphocytic leukemia
AbbVie Inc. secures FDA approval for Venclexta plus acalabrutinib in first-line CLL. Find out why this decision matters for patients, payers, and investors.
A single appeals court ruling puts gene therapy patent economics back in play for Regenxbio Inc. and Sarepta Therapeutics Inc.
Regenxbio Inc. wins a key appeals court reversal against Sarepta Therapeutics Inc. Discover what this means for gene therapy IP and investors.
Why Lucid Group Inc’s latest layoffs matter more than previous restructuring cycles
Lucid Group Inc cuts 12 percent of its workforce to tighten costs and reassure investors. Find out what this means for EV strategy, margins, and what comes next.
Inside OSB Group Plc’s CEO appointment, and what it signals about risk, regulation, and execution
OSB Group Plc appoints Enrique Alvarez Labiano as Chief Executive Officer. Find out what the leadership change signals for strategy, governance, and investors.
FDA clears Bysanti and suddenly Vanda Pharmaceuticals Inc has no margin for execution failure
FDA approval of Bysanti sends Vanda Pharmaceuticals Inc stock higher. Read why execution now matters more than hype in schizophrenia and bipolar markets.
The deeper strategy behind 26,000 tech layoffs led by Amazon.com Inc and ASML Holding N.V.
Amazon.com Inc and ASML Holding N.V. are driving 2026 tech layoffs past 26,000. Read what this means for strategy, talent, and investors.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.